Mylan, Pfizer On The Same Side Over FDA Approval Of Pending Norvasc ANDAs
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is expected to render a decision on approving additional amlodipine ANDAs on April 11.
You may also be interested in...
Apotex Launches Generic Norvasc
Launch undercuts Mylan’s claimed 180-day exclusivity for amlodipine.
Apotex Launches Generic Norvasc
Launch undercuts Mylan’s claimed 180-day exclusivity for amlodipine.
Norvasc Generic Substitution Rate Reaches Nearly 77 Percent
Rate has increased nearly five fold since amlodipine generics hit the market.